According to a new report, published by KBV research, The Global Attention Deficit Hyperactivity Disorder Market size is expected to reach $16.9 billion by 2028, rising at a market growth of 4.0% CAGR during the forecast period.
The Non-stimulants market is experiencing a CAGR of 6.1% during (2022 - 2028). The recent approval of multiple non-stimulant-based drug therapies is the main factor driving the growth of the segment. These innovations have broadened the accessibility of treatment even to those who couldn’t take stimulant drugs for various reasons. In addition, non-stimulant medicines are also prescribed when other medications have detrimental side effects.
The Adults market is leading the Global Attention Deficit Hyperactivity Disorder Market by Demographics in 2021; thereby, achieving a market value of $10 billion by 2028. Adults over 18 who have ADHD struggle to function in social and professional settings as well as in the classroom. Adults having ADHD may struggle to prioritize and concentrate, which can result in missed deadlines, canceled meetings, and neglected social activities. In addition, the inability to restrain impulses can cause a variety of behaviors, such as impatience while driving in line or traffic, mood swings, and angry outbursts.
The Hospital Pharmacy market is anticipated to witness a CAGR of 5.7% during (2022 - 2028). Hospital pharmacists are knowledgeable about medications and may help individuals with ADHD and their caregivers or parents in choosing the proper remedy. Furthermore, the increasing availability of various treatment alternatives and the introduction of new therapeutic medications for better and more effective treatment with fewer side effects have raised the number of patients opting for treatments in hospitals.
The North America market dominated the Global Attention Deficit Hyperactivity Disorder Market by Region in 2021; thereby, achieving a market value of $9.7 billion by 2028. The Europe market is poised to grow a CAGR of 4.3% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 5.6% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/attention-deficit-hyperactivity-disorder-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Eli Lilly And Company, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Johnson & Johnson (Johnson & Johnson Services, Inc.), Lupin Limited, Novartis AG, Takeda Pharmaceutical Company Limited, Mallinckrodt PLC, Purdue Pharma L.P., Aytu BioPharma, Inc. and Supernus Pharmaceuticals, Inc.
By Drug Type
By Demographics
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
